Skip to main content
OpenTrials

Clinical trial condition

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Explore clinical trials studying Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma. Study availability and eligibility vary by location and protocol.

11 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma trial results

Completed

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

NCT01638533

Conditions
Adenocarcinoma, Breast Diseases, Breast Neoplasms, +125 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
View Trial Details
Completed

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

NCT00961220

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +13 more
Locations
  • Henry Ford Hospital Detroit, Michigan, United States
  • Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Case Western Reserve University Cleveland, Ohio, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details
Completed

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

NCT01567709

Conditions
Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Anaplastic Large Cell Lymphoma, +84 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

NCT02520791

Conditions
Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +29 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut, United States
  • Yale University New Haven, Connecticut, United States
View all 23 locations
View Trial Details
Active, Not Recruiting

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

NCT05627245

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +24 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Yale University New Haven, Connecticut, United States
  • University of Kansas Clinical Research Center Fairway, Kansas, United States
  • University of Kansas Cancer Center Kansas City, Kansas, United States
View Trial Details

Related conditions